European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing AuthorizationNov 17, 2021

by Alex Weber
November 18, 2021
A A
Share on LinkedinShare on Twitter

GAITHERSBURG, Md., Nov. 17, 2021 — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for Novavax’ COVID-19 vaccine, which will be marketed in the European Union under the brand name Nuvaxovid™. EMA’s statement may be found here.

“Today’s announcement from EMA brings Novavax another step closer to our goal of ensuring broad global access to our protein-based COVID-19 vaccine across Europe,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “Novavax looks forward to providing an additional vaccine option in Europe, built on a proven, well-understood technology platform, and thanks the European Commission for its ongoing partnership and confidence in our COVID-19 program.”

The company announced earlier this month that it had completed the submission of all data and modules required by EMA for regulatory evaluation of NVX-CoV2373, Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. EMA has indicated that its assessment will proceed under an accelerated timeline, with an opinion issued potentially within weeks.

The chemistry, manufacturing and controls (CMC) data package submitted to EMA and other global regulatory agencies leverages Novavax’ manufacturing partnership with the Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume. It will later be supplemented with data from additional manufacturing sites in Novavax’ global supply chain.

The Novavax/SII vaccine has recently received Emergency Use Authorization (EUA) in Indonesia and the Philippines, and the companies have also filed for emergency authorization in India and for Emergency Use Listing (EUL) with the World Health Organization (WHO). Novavax also announced regulatory filings for its vaccine in the United Kingdom, Australia, New Zealand, Canada and with the WHO. Additionally, Novavax and SK bioscience announced a Biologics License Application (BLA) submission to MFDS in South Korea. Novavax expects to submit the complete package to the U.S. FDA by the end of the year. The brand name NuvaxovidTM has not been authorized by the U.S. FDA.

About the NVX-CoV2373 Phase 3 Trials
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy overall; and the PREVENT-19 trial in the U.S. and Mexico that demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response.

About NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Novavax’ COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 microgram antigen and 50 microgram Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels.

About Matrix-M™ Adjuvant
Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

Tags: < Market

Related Industries

Health

Philips launches AI-powered CT system to accelerate routine radiology and high-volume screening programs

May 18, 2023
Health

Siemens Healthineers opens state-of-the-art education and development center in Erlangen, Germany

May 18, 2023
Health

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology

May 11, 2023
Health

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

May 9, 2023
Health

Changes in Merck Executive Board

May 9, 2023
Health

Health Care Collaboration in Denmark Aims to Reduce Medical Waste

May 9, 2023

BASF partners with BEAUTYSTREAMS to further expand its D’lite digital service for the personal care industry

May 24, 2023

...

Amazon ranks within the top 100 largest corporate taxpayers in France

May 12, 2023

...

Cargill expands its award-winning regenerative agriculture program to Europe

May 24, 2023

...

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology

May 11, 2023

...

Diageo Partners with SAP and IBM on Five-Year Global Digital Transformation Program

May 25, 2023

...

Merck Expands Renewable Energy Through Virtual Power Purchase Agreement with Recurrent Energy

May 16, 2023

...

New Lenovo Supercomputer for Potsdam Institute for Climate Impact Research

May 18, 2023

...

Siemens Healthineers opens state-of-the-art education and development center in Erlangen, Germany

May 18, 2023

...

Working with the European Central Bank on its digital euro prototyping exercise

May 27, 2023

...

BASF’s Coatings division appoints heads for global business units

May 17, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist